A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria

European Urology

Volumn 70, Issue 6, 2016, Pages 916-919

  Dahmcke, Christina M ^a   Steven, Kenneth E ^b   Larsen, Louise K ^a   Poulsen, Asger L ^c   Abdul Al, Ahmad ^a   Dahl, Christina ^a   Guldberg, Per ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Kirurgisk Urologisk Klinik   (Denmark)

Author keywords

Bladder cancer; DNA methylation; Driver mutations; Droplet digital PCR; Noninvasive detection; Urinary biomarkers; Urine filtration; Urothelial carcinoma

Indexed keywords

CELL DNA; CYCLIN A1; EOMESODERMIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; ONECUT2 PROTEIN; PEPTIDES AND PROTEINS; PROTEIN BCL 2; SALL3 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FALSE NEGATIVE RESULT; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MEMBRANE FILTER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; STANDARD; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINE SAMPLING; ADOLESCENT; ADULT; AGED; BLADDER TUMOR; COMPLICATION; CYTOLOGY; FEMALE; GENETICS; MALE; MIDDLE AGED; URINE; UROGRAPHY; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYSTOSCOPY; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; HEMATURIA; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER NEOPLASMS; URINE; UROGRAPHY; YOUNG ADULT;

EID: 84992560936     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.06.035     Document Type: Article

References (12)

1. [1] Khadra, M.H., Pickard, R.S., Charlton, M., Powell, P.H., Neal, D.E., A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 163 (2000), 524–527.
2. [2] Rink, M., Babjuk, M., Catto, J.W., et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol 64 (2013), 624–638.
3. [3] Sapre, N., Anderson, P.D., Costello, A.J., Hovens, C.M., Corcoran, N.M., Gene-based urinary biomarkers for bladder cancer: An unfulfilled promise?. Urol Oncol, 32, 2014 48-17.
4. [4] Andersson, E., Dahmcke, C.M., Steven, K., Larsen, L.K., Guldberg, P., Filtration device for on-site collection, storage and shipment of cells from urine and its application to DNA-based detection of bladder cancer. PLoS ONE, 10, 2015, e0131889.
5. [5] Taly, V., Pekin, D., El, A.A., Laurent-Puig, P., Detecting biomarkers with microdroplet technology. Trends Mol Med 18 (2012), 405–416.
6. [6] Zuiverloon, T.C., Tjin, S.S., Busstra, M., et al. Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay. J Urol 186 (2011), 707–712.
7. [7] Kandimalla, R., Masius, R., Beukers, W., et al. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine. Clin Cancer Res 19 (2013), 4760–4769.
8. [8] Yu, J., Zhu, T., Wang, Z., et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 13 (2007), 7296–7304.
9. [9] Allory, Y., Beukers, W., Sagrera, A., et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65 (2014), 360–366.
10. [10] Li, C., Wu, S., Wang, H., et al. The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer. Oncotarget 6 (2015), 19542–19551.
11. [11] Borah, S., Xi, L., Zaug, A.J., et al. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 347 (2015), 1006–1010.
12. [12] Birkenkamp-Demtröder, K., Nordentoft, I., Christensen, E., et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol 70 (2016), 75–82.